|
The pair will harness AI to discover and develop recombinases for precise, large-scale gene editing.
|
 |
|
A PRV is issued by the FDA to sponsors whose products address certain rare paediatric diseases.
|
|
|
The collaboration leverages Fosun Pharma’s research and manufacturing strengths, as well as Arcera’s access to international markets.
|
|
|
With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.
|
|
|
The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.
|
|
